BRKR

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2003, for Bruker BioSciences Corporation (formerly Bruker Daltonics Inc.). The Company designs, manufactures, and markets life science systems based on mass spectrometry and field analytical systems. The financial statements presented reflect the Company's operations prior to its merger with Bruker AXS Inc., which closed on July 1, 2003.

Key Financial Metrics

Liquidity: As of June 30, 2003, the Company held $46.8 million in cash and short-term investments. Total current liabilities were $67.7 million, resulting in a working capital deficit of approximately $12.7 million. The Company maintains revolving lines of credit in the U.S., Germany, and Japan.

Material Changes vs. Prior Period

• Revenue Growth: Product revenue increased 23.2% ($6.5 million) for the quarter and 27.8% ($14.9 million) for the six months compared to the prior year periods. Growth was driven by organic expansion in life science product lines (specifically TOF) and favorable foreign currency impacts (approx. 18% for the quarter).
• Profitability Improvement: The Company reported a net loss of $0.2 million for the quarter, a significant improvement from the $4.2 million net loss in the same period of 2002. The six-month net loss narrowed to $1.3 million from $3.3 million.
• Cost Structure: Cost of product revenue increased 30.5% for the quarter, outpacing revenue growth due to an unfavorable foreign currency impact (strengthening Euro) and a change in sales mix. Gross margin was impacted by an unprofitable contract with the U.K. Ministry of Defense (MOD).
• One-Time Items:
  • Reversal of Liability: A $1.9 million reversal of an accrued contract liability was recorded in Q2 2003 following a settlement with the MOD regarding liquidated damages.
  • Merger Costs: $0.9 million in merger-related costs were incurred in Q2 2003 (totaling $2.8 million for the six months) associated with the acquisition of Bruker AXS.
  • Investment Write-downs: The prior year period included a $4.4 million charge for the write-down of investments in proteomics content companies, which was not present in 2003.

Outlook, Risks, and Unusual Items

• Merger with Bruker AXS: The merger closed on July 1, 2003, creating a combined entity focused on life science and materials research. The transaction was valued at approximately $155 million, increasing outstanding shares by 31.5 million. Pro forma results indicate higher revenue but continued net losses.
• Foreign Currency Risk: The Company is exposed to currency fluctuations, particularly the Euro, as most manufacturing occurs in Germany. The strengthening Euro negatively impacted cost of revenue margins in 2003.
• Legal Contingencies: The Company resolved a significant dispute with the U.K. Ministry of Defense, reversing a $1.9 million reserve. Management believes no other pending legal proceedings will materially impact financial condition.
• Liquidity Outlook: Management anticipates existing capital resources will meet operating and investing needs through the end of 2003. The Company has renegotiated a $5.8 million short-term note into long-term debt to improve liquidity.

Investor Verification Checklist

• Merger Accounting: Verify the final purchase price allocation and goodwill recognition for the Bruker AXS merger in the subsequent 10-K filing.
• Currency Hedging: Monitor future disclosures regarding hedging strategies to mitigate the impact of the Euro on cost of revenue.
• MOD Contract Performance: Confirm that the settlement with the U.K. Ministry of Defense remains final and that no further claims or costs arise from this contract.
• Debt Covenants: Review the terms of the renegotiated long-term notes and revolving credit facilities to ensure compliance with covenants given the working capital deficit.
• Pro Forma Accuracy: Compare actual post-merger results against the unaudited pro forma financial information provided in Note 10 to assess the accuracy of the merger's financial impact.